News

Children as young as 2 years may soon have access to the first-ever oral treatment for sudden hereditary angioedema (HAE) attacks. New Phase 3 data from developer Kalvista Pharmaceuticals suggests that Ekterly (sebetralstat) is both safe and effective for young children, offering a needle-free alternative to the…

For people in Puerto Rico with hereditary angioedema (HAE), long-term treatment with Takhzyro (lanadelumab) is safe and effective for preventing swelling attacks, new real-world data show. Specifically, more than two years of treatment with the approved injection medication safely and effectively maintained low HAE attack rates among people of Hispanic or…

A woman in her 80s who had taken the same blood pressure medication for 11 years without issue suddenly developed a life-threatening reaction, marked by angioedema (swelling) in both her digestive tract and airway, a new case report reveals. The rare dual presentation initially mimicked a bowel obstruction, nearly…

A 56-year-old man’s recurring abdominal pain and bowel issues were finally traced back to a rare genetic condition, hereditary angioedema (HAE), according to a recent case report. Despite the patient’s age and lack of family history, genetic testing identified a mutation in the SERPING1 gene, and his symptoms were…

Use of Dawnzera (donidalorsen) — approved in the U.S. as a preventive treatment for hereditary angioedema (HAE) in patients ages 12 and older — led to sustained reductions in the rate of swelling attacks, accompanied by quality of life improvements, for as long as nearly four years among…

The U.S. Food and Drug Administration (FDA) has granted fast-track status to BW-20805, Argo Biopharma‘s long-acting investigational therapy for hereditary angioedema (HAE), which is intended to be given every three to six months to prevent swelling attacks in people with HAE. Most available HAE drugs must be taken…

Treatment with onvuzosiran (ADX-324), Adarx Pharmaceuticals’ experimental treatment for hereditary angioedema (HAE), was well tolerated and lowered kallikrein levels and the frequency of swelling attacks, according to interim data from a Phase 1/2 trial. The data were presented at the American Academy of Allergy, Asthma & Immunology annual scientific meeting,…

On-demand treatment with deucrictibant, an experimental oral small molecule in the pipeline at Pharvaris, provides rapid relief from sudden swelling due to hereditary angioedema (HAE) and, when taken daily for up to three years, can reduce the frequency of attacks over the long term. That’s according to…

For sudden attacks of hereditary angioedema (HAE), many patients prefer — and remain satisfied with — using Ekterly (sebetralstat) oral tablets from Kalvista Therapeutics over other on-demand treatment options, because they are taken by mouth and allow swelling to be treated earlier, with sustained benefits. That’s according to new…

Treatment with tranexamic acid does not appear to improve survival in people who develop angioedema after taking angiotensin-converting enzyme inhibitors (ACEIs) to lower blood pressure, a large U.S. study found. Researchers compared more than 1,000 patients who received tranexamic acid with others who did not, and found no difference…